A Boon For Investors! Pharma Giant Recommends Massive Dividend of Rs 117; A Solid Move For Shareholder Value?

One of the top pharmaceutical companies listed on the BSE 500 index is Sanofi India. Sanofi, which has been in India for almost 70 years, specialises in wellness, prevention through vaccinations, treatment, patient assistance, and more. Sanofi India provides products for consumers in India and more than 60 other countries at its top-notch manufacturing facility in Goa. One of Sanofi's four global talent centres is situated in Hyderabad, India, and offers a variety of services all over the world. Following the Board's recommendation of a large dividend for the fiscal year that concluded on December 31, 2024, Sanofi India's shares closed Friday's trading session on the BSE 0.58% higher at Rs 5025.95, with a market capitalisation of Rs 11,574.76 Cr.

Sanofi India Dividend

The Board of Directors "Recommended a final dividend of Rs 117/- per equity share of the face value of Rs 10 each for the Financial Year ended 31st December 2024, subject to the approval of Shareholders at the ensuing 69th Annual General Meeting," said Sanofi India in a stock exchange filing.

Following shareholder approval at the company's upcoming annual general meeting, the dividend will be paid to the eligible shareholders.

Sanofi India Financials

Sanofi India Limited's (SIL) board approved the company's Q4 and year-to-date financial reports, which ended on December 31, 2024. Sanofi India Ltd. (SIL) reported sales of Rs 514.9 crore, up 9.7% year-over-year (YoY) from Rs 469.2 crore in the same period last year. EBITDA increased from Rs 99.6 crore in Q4FY24 to Rs 118.3 crore in Q4FY25, an 18.8% YoY growth. From Rs 137.7 crore in the year-ago quarter to Rs 91.3 crore in the current quarter, the company's net profit fell 33.7%.

Rodolfo Hrosz - Managing Director, Sanofi India Limited said, "In a year of significant transformation for the company, we have successfully brought to market Soliqua® - our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India."

Sanofi India Share Price Target

Mandar Bhojane - Equity Research Analyst at Choice Broking said, "Sanofi India is trading at ₹5,120 and remains under selling pressure, forming lower lows and lower highs, signaling a sustained bearish trend. The stock has declined 33% from its all-time high and breached the critical ₹5,265 support, now trading below the 20-day, 50-day, and 200-day EMAs, reinforcing a negative outlook. The RSI stands at 38.26 and continues to decline, indicating rising selling momentum. Despite the weakness, Sanofi surged 6% in morning trade on Friday after strong Q4 results and a ₹117 per share dividend announcement, reaching ₹5,324."

"However, the stock later trimmed gains by nearly 7% before recovering around 4%, making the session highly volatile. The ₹4,800 level is expected to act as strong support due to historical buying interest. A rebound may occur if the stock stabilizes at this level, but a breakdown below ₹4,800 could trigger further downside. Given current market conditions, traders and investors should exercise caution and wait for confirmation of price action before initiating fresh positions," the analyst further recommended.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.